Management of Carotid Artery Stenosis for Stroke Prevention
For symptomatic carotid stenosis ≥50%, carotid endarterectomy (CEA) should be performed within 2 weeks of the ischemic event, combined with dual antiplatelet therapy (aspirin plus clopidogrel) for at least 21 days, as this approach provides the greatest reduction in recurrent stroke risk. 1
Symptomatic Carotid Stenosis (Recent TIA, Stroke, or Amaurosis Fugax)
Immediate Medical Management
Start dual antiplatelet therapy (DAPT) immediately with aspirin and clopidogrel for at least 21 days (up to 90 days may be considered based on bleeding risk) in all patients with symptomatic carotid stenosis who are not immediately revascularized. 1
All symptomatic patients require assessment by a multidisciplinary vascular team including a neurologist to determine optimal treatment strategy. 1
Revascularization Timing and Indications
For stenosis ≥70%: CEA is strongly recommended and should be performed as soon as the patient is neurologically stable after 48 hours but definitely within 14 days of symptom onset. 1, 2, 3
For stenosis 50-69%: CEA should be considered, though the benefit is more modest than with higher-grade stenosis. 1, 2
For stenosis <50%: CEA is not beneficial and medical management alone is appropriate. 1
CEA vs. Carotid Artery Stenting (CAS) in Symptomatic Patients
CEA remains the first-line treatment for average surgical risk patients with symptomatic stenosis ≥50%. 1, 3
CAS may be considered in patients <70 years old with symptomatic stenosis ≥50%, or in high surgical risk patients where the multidisciplinary team deems CEA too risky—but only if the procedural stroke/death rate does not exceed 6%. 1, 2
CEA has higher rates of myocardial infarction, cranial nerve palsy, and access site hematoma, while CAS has higher rates of periprocedural minor (non-disabling) stroke. 1, 4
Transcarotid artery revascularization (TCAR) shows promising registry data with 30-day stroke/death rates <3%, though no randomized controlled trials exist yet. 1
Post-Revascularization Antiplatelet Therapy
After CEA: Clopidogrel can be stopped after surgery; long-term single antiplatelet therapy (SAPT) should be continued. 1
After CAS: Continue DAPT with aspirin and clopidogrel for 4 weeks post-procedure, then transition to long-term SAPT. 1
Asymptomatic Carotid Stenosis
When to Consider Revascularization
Revascularization should only be considered in asymptomatic patients with stenosis 60-99% who meet ALL of the following criteria: 1, 5
- Life expectancy >5 years
- Presence of high-risk features (see below)
- Documented institutional perioperative stroke/death rate <3%
- Patient age >75 years for average surgical risk patients
- Patient understanding and acceptance of risks/benefits
High-Risk Features That Favor Intervention
High-risk plaque characteristics include: 6, 7
- Large lipid cores with thin fibrous caps (<165 μm)
- Intraplaque hemorrhage
- Surface ulceration or fissures
- Intraluminal thrombi
- Carotid webs or dissections
- Rim sign on imaging
Treatment Options for Asymptomatic Stenosis
For average surgical risk patients >75 years with 60-99% stenosis and high-risk features: CEA plus optimal medical therapy (OMT) should be considered. 1
For high surgical risk patients with 60-99% stenosis and high-risk features: CAS plus OMT may be considered. 1
For average surgical risk patients with 60-99% stenosis and high-risk features: CAS may be considered as an alternative to CEA. 1
Routine revascularization is NOT recommended in asymptomatic patients without high-risk features or with life expectancy <5 years. 1
Optimal Medical Therapy for All Patients
Regardless of whether revascularization is performed, all patients with carotid stenosis require: 6
- Antiplatelet therapy: Aspirin or clopidogrel long-term
- High-intensity statin therapy: For lipid lowering and plaque stabilization
- Blood pressure control: Target <140/90 mmHg (or <130/80 mmHg in selected patients)
- Diabetes management: If present
- Smoking cessation: Mandatory
- Lifestyle modifications: Diet, exercise, weight management
Special Populations
Patients Requiring Coronary Artery Bypass Grafting (CABG)
For symptomatic carotid stenosis 50-99% requiring CABG: Perform CEA before or concomitant with CABG to reduce stroke risk. 1, 3
For asymptomatic carotid stenosis requiring CABG: There is no convincing evidence that prophylactic CEA reduces stroke risk; most perioperative strokes are mechanistically unrelated to carotid disease. 1
Fibromuscular Dysplasia (FMD)
- Revascularization is NOT recommended for asymptomatic FMD regardless of stenosis severity. 1
- Carotid angioplasty with or without stenting is reasonable for symptomatic FMD causing retinal or hemispheric ischemia. 1
- Antiplatelet therapy should be administered to prevent thromboembolism, though optimal regimen is not established. 1
Critical Pitfalls to Avoid
Do not perform CEA within the first 48 hours of symptom onset in patients with acute carotid occlusion, major neurological deficit, large middle cerebral artery infarction (>1/3 territory), pre-existing parenchymal hemorrhage, or impaired consciousness—these patients have increased risk of hemorrhagic transformation. 1
Do not offer revascularization to asymptomatic patients if your institutional perioperative stroke/death rate exceeds 3%, as the intervention will cause more harm than benefit. 1, 5
Do not assume all strokes in patients with carotid stenosis are embolic—nonstenotic (<50%) carotid disease with high-risk plaque features (intraluminal thrombi, webs, dissections, rim sign) can cause ipsilateral stroke and should be evaluated. 7
Do not rely solely on degree of stenosis—plaque morphology and high-risk features are increasingly important in risk stratification and treatment decisions. 6, 7